Items where Greenwich Author is "Leach, Dr Michael"
Up a level |
Cyclic Triazo Sodium channel blockers
University of Greenwich (2017) HK1170726 (A1)2017-06-02 Cyclic triazo sodium channel blockers. HK1179726 (A1).
Cytokines, treatment of multiple sclerosis
BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.
Cytokines; Interferon gamma; Triazines
University of Greenwich (2016) Triazine derivatives as interferon gamma inhibitors. WO 2016/109978 A1.
Interferon gamma inhibitors, triazine derivatives
University of Greenwich (2018) Triazine derivatives as interferon gamma inhibitors. EP 3307273 (A1).
Interleukin Inhibitors
University of Greenwich (2021) Interleukin Inhibitors. WO2021/214494 A1.
Multiple sclerosis, polyunsaturated fatty acids
BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).
Neurodegenerative disease, multiple sclerosis, uveitis
University of Greenwich (2015) Medical uses of triazines. .
Neuroprotection Sodium channels Multiple sclerosis
University of Greenwich, London, UK (2014) US2014155403 Cyclic triazo and diazo sodium channel blockers. .
Neuroprotection, Sodium channel blockers
University of Greenwich, London UK (2014) ES24629727 (T3): New medical use of triazines. .
Neuroprotective, Multiple sclerosis, Uveitis and other diseases.
University of Greenwich, UK (2015) AU2014280981: Cyclic Triazo and Diazo channel blockers. .
Polyunsaturated fatty acids, neurodegenerative diseases
BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.
Polyunsaturated fatty acids, treatment of multiple sclerosis
BTG International Limited (2004) Use of triglyceride oils containing gamma-linolenic residues and linoleic acid residues for the treatment of neurodegenerative disease. WO2004/100943 A1.
Sodium channel blockers, Neuroprotection
University of Greenwich, UK (2012) KR20120048593 Cyclic triazo sodium channel blockers. KR20120048593 (A).
Sodium channel blockers; Multiple sclerosis; Neurological disorders
Michael Leach (2014) US2014243343 (A1)Cyclic triazo sodium channel blockers. .
Sodium channel blockers; Neuroprotection
University of Greenwich (2016) Cyclic triazo and diazo sodium channel blockers US divisional. US2016/0311784A1.
TREK channel, TRESK channel, K2P cannel, lamotrigine, Sipatrigine, CEN-092
Walsh, Yvonne, Leach, Michael ORCID: 0000-0002-9859-1325 , Veale, Emma and Mathie, Alistair (2021) Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine, and CEN-092. Biochemistry and Biophysics Reports, 26:101021. ISSN 2405-5808 (doi:https://doi.org/10.1016/j.bbrep.2021.101021)
Treatment of multiple sclerosis
BTG International Limited (2005) Treatment of neurodegenerative conditions. WO2005/018632/A1.
Triazines, Neurodegenerative disorders, multiple sclerosis
University of Greenwich, UK (2015) US9000155: Cyclic triazo sodium channel blockers. .
Triazines, Sodium channel blockers, Neurodegeneration
University of Greenwich, London UK (2014) HK1129206 (A1): New medical use of triazine derivatives. .
Triazines; Sodium channel blockers; Interferon gamma inhibitors
University of Greenwich (2018) Triazine derivatives as interferon gamma inhibitors. US2018169105.
borage, gamma-linolneic acid, GLA, monocyte chemoattractant protein 1, chronic inflammatory disease
Xiang, M., Pinto, E., Rahman, M.A., Leach, M. ORCID: 0000-0002-9859-1325 and Harbige, L.S. (2008) Borage (Borago officinalis) oil supplementation in relation to monocyte chemoattractant protein 1 expression in healthy subjects. Proceedings of the Nutrition Society, 67 (OCE1). E44-E44. ISSN 0029-6651 (Print), 1475-2719 (Online) (doi:https://doi.org/10.1017/S0029665108006538)
breast cancer; bone metastasis; IL-1beta
Zhou, Jiabao, Down, Jennifer M, George, Christopher N, Murphy, Jessica, Lefley, Diane V, Tulotta, Claudia, Alsharif, Marwa A, Leach, Michael ORCID: 0000-0002-9859-1325 and Ottewell, Penelope D (2022) Novel methods of targeting IL-1 signalling for the treatment of breast cancer bone metastasis. Cancers, 14 (19):4816. ISSN 2072-6694 (Online) (doi:https://doi.org/10.3390/cancers14194816)
central nervous system drugs, pyrimidines, lamotrigines, lamotrigine, voltage-gated Na+ channel blockers, gated sodium channels, crystal structures and drug design
Palmer, Rex A., Potter, Brian S., Helliwell, Madeleine, Leach, Michael J. ORCID: 0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) Central nervous system drugs: Low temperature X-ray structures of (I) the base 5-(2,3-dichlorophenyl)-2,4-diamino-6-fluoromethyl-pyrimidine (4030W92) and (II) 5-(2,6-dichlorophenyl)-1-H-2,4-diamino-6-methyl-pyrimidine methanesulphonic acid salt (227C89). Journal of Chemical Crystallography, 39 (1). pp. 36-41. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:https://doi.org/10.1007/s10870-008-9428-5)
central nervous system drugs, pyrimidines, lamotrigines, voltage gated Na+ channel inhibitors, crystal structures and drug design
Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: 0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) Low temperature X-ray structures of two crystalline forms (I) and (II) of the pyrimidine derivative and sodium channel blocker BW1003C87: 5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine. Journal of Chemical Crystallography, 38 (6). pp. 407-411. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:https://doi.org/10.1007/s10870-008-9319-9)
central nervous system drugs, pyrimidines, lamotrigines, voltage-gated Na+ channel inhibitors, crystal structures and drug design
Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: 0000-0002-9859-1325 and Chowdhry, Babur Z. (2007) X-ray crystallographic structures of neuroprotective pyrimidine derivatives: (I) the mesylate salt of BW1003C87 and (II) sipatrigine base. Journal of Chemical Crystallography, 37 (11). pp. 771-777. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:https://doi.org/10.1007/s10870-007-9248-z)
central nervous system drugs, triazines, lamotrigines, voltage gated Na+ channel inhibitors, crystal structures and drug design
Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: 0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) X-ray crystallographic structures of two lamotrigine analogues: (I) 3,5-diamino-6-(2-chlorophenyl)-1,2,4-triazine water solvate and (II) 3,5-diamino-6-(3,6-dichlorophenyl)-1,2,4-triazine methanol solvate. Journal of Chemical Crystallography, 38 (5). pp. 387-392. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:https://doi.org/10.1007/s10870-008-9320-3)
Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: 0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) Low temperature X-ray crystallographic structures of two lamotrigine analogues: (I) 2-methyl,3-amino, 5-imino-6-(2,3-dichlorophenyl)-1,2,4-triazine water solvate and (II) 2-methyl,3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate, hemi-hydrate. Journal of Chemical Crystallography, 38 (4). pp. 255-260. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:https://doi.org/10.1007/s10870-008-9318-x)
cytokine storm syndrome; cytokine release syndrome
Leach, Michael, and Williams, Paul, University of Greenwich (2023) Diazine and triazine compounds to treat cytokine storm syndrome US 2023/0165869 A1. US2023/0165869A1.
diazines; triazines; cytokine storm; cytokines
Leach, Michael, and Williams, Paul, University of Greenwich (2021) Diazine and triazine compounds to treat cytokine storm syndrome. WO2016198878A1.
fatty acids, pathogenesis, treatment, multiple sclerosis
Harbige, L. S., Hollifield, R. D., Pinto, E., Xiang, M., Leach, M. ORCID: 0000-0002-9859-1325 and Sharief, M. K. (2006) Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. In: 7th Congress of the ISSFAL, International Society for the Study of Fatty Acids & Lipids (ISSFAL 2006), 23–28 July 2006, Cairns Convention Centre, Cairns, Queensland, Australia. (Unpublished)
fatty acids, w-6 fatty acid, chemokine, blood mononuclear cells, case studies
Pinto, E., Xiang, M., Leach, M. ORCID: 0000-0002-9859-1325 and Harbige, L.S. (2006) Effects of ω-6 fatty acid supplementation on chemokine production by peripheral blood mononuclear cells from healthy volunteers. In: 7th Congress of the ISSFAL, International Society for the Study of Fatty Acids & Lipids (ISSFAL 2006), 23–28 Jul 2006, Cairns, Queensland, Australia. (Unpublished)
lamotrigine, multiple sclerosis, use patent
BTG International Limited (2004) Treatment of neurodegenerative conditions. US 2004/0229873 Al.
monocyte chemoattractant protein 1, 15-deoxy-12,14-prostaglandin J2, gamma-linolenic acid
Xiang, M., Pinto, E., Rahman, M.A., Leach, M. ORCID: 0000-0002-9859-1325 and Harbige, L.S. (2010) Decreased monocyte chemoattractant protein 1 and relationship with 15-deoxy-delta 12,14- prostaglandin J2 in gamma-linolenic acid supplemented healthy subjects. Proceedings of the Nutrition Society, 69 (OCE3). E325-E325. ISSN 0029-6651 (Print), 1475-2719 (Online) (doi:https://doi.org/10.1017/S002966511000114X)
multiple sclerosis, MS, borage, BGC20-884
Harbige, L.S., Pinto, E., Xiang, M., Leach, M. ORCID: 0000-0002-9859-1325 and Sharief, M. K. (2008) PUFA in the pathogenesis and treatment of patients with multiple sclerosis. Proceedings of the Nutrition Society, 67 (OCE1). E21. ISSN 0029-6651 (Print), 1475-2719 (Online) (doi:https://doi.org/10.1017/S0029665108006307)
multiple sclerosis, central nervous system, neurodegeneration
BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).
multiple sclerosis, neurodegeneration, central nervous system
BTG International Ltd. (2011) Treatment of neurodegenerative conditions. JP2011144195.
phospholipids, treatment of multiple sclerosis
BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.
polyunsaturated fatty acids, treatment of multiple sclerosis
BTG International Ltd (2010) Treatment of neurodegenerative conditions. US2010/0113810 A1.
structured phospholipids, cytokines, multiple sclerosis
BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.
triazines, medical use
University of Greenwich, Old Royal Naval College Park Row, Greenwich, London SE10 9LS (2008) New medical use of triazine derivatives. WO/2008/007149.
triazines, sodium channel blockers
University of Greenwich, Old Royal Naval College Park Row, Greenwich London SE10 9LS (2009) Cyclic triazo and diazo sodium channel blockers. WO/2009/090431.
triazines, sodium channel blockers, central nervous system diseases
University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.
triglycerides, neurodegenerative diseases, multiple sclerosis
BTG International Limited (2008) Treatment of neurodegenerative conditions. GB2442161/B.
voltage-gated sodium channels, BW202W92, BW203W92, X-ray crystallographic structures
Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: 0000-0002-9859-1325 , Jenkins, Terence C. and Chowdhry, Babur Z. (2010) An absolute structure template for a unique voltage-gated sodium channel binding site. MedChemComm, 1 (1). pp. 45-49. ISSN 2040-2503 (Print), 2040-2511 (Online) (doi:https://doi.org/10.1039/C0MD00043D)
voltage-gated sodium channels, binding site, BW202W92
Riddall, Dieter R., Leach, Michael J. ORCID: 0000-0002-9859-1325 and Garthwaite, John (2006) A novel drug binding site on voltage-gated sodium channels in rat brain. Molecular Pharmacology, 69 (1). pp. 278-287. ISSN 1521-0111 (Online) (doi:https://doi.org/10.1124/mol.105.015966)